Thomas Scherer

Thomas Scherer

Auto-generated profile, based on publicly available information

Thomas Scherer

Division of Endocrinology and Metabolism, Department of Medicine III, Medical University of Vienna, Vienna, Austria

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2021 in Nature Reviews Endocrinology
Verified
Journal Article
Closed access
PDF file
TSThomas Scherer
Thomas Scherer
KSKenichi Sakamoto
Kenichi Sakamoto
CBChristoph Buettner
Christoph Buettner

20 June 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
MHMartina Theresa Hackl
Martina Theresa Hackl
CFClemens Fürnsinn
Clemens Fürnsinn
CSChristina Maria Schuh
Christina Maria Schuh
Martin KrssakMartin Krssak
Martin Krssak
FCFabrizia Carli
Fabrizia Carli
TSThomas Scherer
Thomas Scherer
Hepatic steatosis develops when lipid influx and production exceed the liver’s ability to utilize/export triglycerides. Obesity promotes steatosis and is characterized by leptin resistance. A role of leptin in hepatic lipid handling is highlighted by the observation that recombinant leptin reverses steatosis of hypoleptinemic patients with lipodystrophy by an unknown mechanism. Since leptin mainly functions via CNS signaling, we here examine in rats whether leptin regulates hepatic lipid flux via the brain in a series of stereotaxic infusion experiments. We demonstrate that brain leptin protects from steatosis by promoting hepatic triglyceride export and decreasing de novo lipogenesis independently of caloric intake. Leptin’s anti-steatotic effects are generated in the dorsal vagal complex, require hepatic vagal innervation, and are preserved in high-fat-diet-fed rats when the blood brain barrier is bypassed. Thus, CNS leptin protects from ectopic lipid accumulation via a brain-vagus-liver axis and may be a therapeutic strategy to ameliorate obesity-related steatosis.

10 October 2022 in Cell Metabolism
Verified
Journal Article
Closed access
MMMatthäus Metz
Matthäus Metz
MBMarianna Beghini
Marianna Beghini
PWPeter Wolf
Peter Wolf
LPLorenz Pfleger
Lorenz Pfleger
MHMartina Hackl
Martina Hackl
TSThomas Scherer
Thomas Scherer

9 February 2016 in Diabetes
Verified
Journal Article
Open access
PDF file
TSThomas Scherer
Thomas Scherer
CLClaudia Lindtner
Claudia Lindtner
JOJames O’hAre
James O’hAre
MHMartina Hackl
Martina Hackl
EZElizabeth Zielinski
Elizabeth Zielinski
CBChristoph Buettner
Christoph Buettner
Hepatic steatosis is common in obesity and insulin resistance and results from a net retention of lipids in the liver. A key mechanism to prevent steatosis is to increase secretion of triglycerides (TG) packaged as VLDLs. Insulin controls nutrient partitioning via signaling through its cognate receptor in peripheral target organs such as liver, muscle, and adipose tissue and via signaling in the central nervous system (CNS) to orchestrate organ cross talk. While hepatic insulin signaling is known to suppress VLDL production from the liver, it is unknown whether brain insulin signaling independently regulates hepatic VLDL secretion. Here, we show that in conscious, unrestrained male Sprague Dawley rats the infusion of insulin into the third ventricle acutely increased hepatic TG secretion. Chronic infusion of insulin into the CNS via osmotic minipumps reduced the hepatic lipid content as assessed by noninvasive 1H-MRS and lipid profiling independent of changes in hepatic de novo lipogenesis and food intake. In mice that lack the insulin receptor in the brain, hepatic TG secretion was reduced compared with wild-type littermate controls. These studies identify brain insulin as an important permissive factor in hepatic VLDL secretion that protects against hepatic steatosis.

27 April 2023 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
PBPetr Bednarik
Petr Bednarik
DGDario Goranovic
Dario Goranovic
ASAlena Svátková
Alena Svátková
FNFabian Niess
Fabian Niess
LHLukas Hingerl
Lukas Hingerl
Wolfgang BognerWolfgang Bogner
Wolfgang Bogner

14 June 2024 in European Journal of Neurology
Verified
Journal Article
Open access
PSProf. Dr. Benedikt Schoser
Prof. Dr. Benedikt Schoser
NBNadine A. M. E. van der Beek
Nadine A. M. E. van der Beek
ABAlexander Broomfield
Alexander Broomfield
EBEsther Brusse
Esther Brusse
JDJordi Díaz-Manera
Jordi Díaz-Manera
APAns T. van der Ploeg
Ans T. van der Ploeg
Background and purpose: Two novel enzyme replacement therapies (ERTs), studied in phase 3 trials in late‐onset Pompe patients, reached marketing authorization by the European Medicines Agency in 2022 and 2023. The European Pompe Consortium (EPOC) updates and extends the scope of the 2017 recommendations for starting, switching and stopping ERT.Methods: The European Pompe Consortium consists of 25 neuromuscular and metabolic experts from eight European countries. This update was performed after an in‐person meeting, three rounds of discussion and voting to provide a consensus recommendation.Results: The patient should be symptomatic, that is, should have skeletal muscle weakness or respiratory muscle involvement. Muscle magnetic resonance imaging findings showing substantial fat replacement can support the decision to start in a patient‐by‐patient scenario. Limited evidence supports switching ERT if there is no indication that skeletal muscle and/or respiratory function have stabilized or improved during standard ERT of 12 months or after severe infusion‐associated reactions. Switching of ERT should be discussed on a patient‐by‐patient shared‐decision basis. If there are severe, unmanageable infusion‐associated reactions and no stabilization in skeletal muscle function during the first 2 years after starting or switching treatment, stopping ERT should be considered. After stopping ERT for inefficacy, restarting ERT can be considered. Six‐monthly European Pompe Consortium muscle function assessments are recommended.Conclusions: The triple‐S criteria on ERT start, switch and stop include muscle magnetic resonance imaging as a supportive finding and the potential option of home infusion therapy. Six‐monthly long‐term monitoring of muscle function is highly recommended to cover insights into the patient's trajectory under ERT.